Fig. 3.

Evobrutinib reduces expression of activation markers on B and T cells. Oral treatment of C57/BL6 mice with vehicle or 1, 3 or 10 mg/kg evobrutinib started 7 days prior to immunization with 75 µg conformational MOG1-117 protein. Splenic cells were analyzed 12 days after immunization by flow cytometry. Expression of MHCII, CD69, CD86 and CD80 on a B cells and b Monocytes. Expression of CD25 or CD69 and frequency of CD44^hi cells of c) CD4⁺ T cells and d CD8⁺ T cells. Median, n = 16 pooled from 4 to 8 independent experiments, *p < 0.05, **p < 0.01, ****p < 0.0001